WA
REGN icon

Winfield Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Winfield Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-15
Closed -$6K – 768
2016
Q3 		$6K Hold
15
– – ﹤0.01% 390
2016
Q2 		$5K Buy
+15
New +$5.78K ﹤0.01% 408

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Winfield Associates's REGN Position: Q4 2016 in Review

Winfield Associates sold out of Regeneron Pharmaceuticals (REGN) in Q4 2016, closing a stake of 15 shares — an estimated $6K sold.

Winfield Associates first reported a position in REGN in Q2 2016 and held it in 2 quarters. The position peaked at $6K in Q3 2016. 576 funds tracked by Wall St. Rank hold REGN as of Q4 2016.

  • Winfield Associates reported no remaining Regeneron Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Winfield Associates sold 15 Regeneron Pharmaceuticals shares in Q4 2016, an estimated $6K.
  • Winfield Associates first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Winfield Associates's Regeneron Pharmaceuticals position peaked at $6K in Q3 2016.
  • 576 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2016.

Based on Winfield Associates's 13F filing for Q4 2016, filed 20 Jan 2017.